Core Viewpoint - The article discusses the rise of medical tourism in China, highlighting the integration of healthcare services with travel experiences, driven by policies like the 240-hour visa-free transit and the "Healthy China 2030" strategy, which aims to make healthcare services more accessible and appealing to international visitors [5][14]. Group 1: Medical Tourism Growth - The implementation of the 240-hour visa-free policy has led to a significant increase in foreign visitors to China, with 40.6 million arrivals in the past year, marking a 27.2% year-on-year growth [5]. - Chinese hospitals, particularly in major cities like Beijing, Shanghai, and Shenzhen, are increasingly catering to international patients, offering competitive pricing and efficient services compared to Western countries [8][13]. - The cost of medical procedures in China is significantly lower than in the U.S.; for example, a heart bypass surgery costs approximately $40,000 in China compared to $130,000 in the U.S. [8]. Group 2: Unique Offerings and Experiences - Chinese hospitals are not only providing medical services but also integrating cultural experiences, such as traditional Chinese medicine, into their offerings, which enhances the appeal for international tourists [15]. - The article highlights successful cases of foreign patients receiving treatment in China, showcasing the effectiveness and affordability of the services provided [7][14]. - The combination of medical treatment and tourism is creating a unique experience that is gaining recognition among international visitors, with some even traveling to China for childbirth [14]. Group 3: Future Projections and Market Potential - The medical tourism market in China is projected to exceed 300 billion yuan by 2029, driven by the dual forces of the "Healthy China" strategy and rising consumer spending [17]. - The article draws parallels with other countries that have successfully developed their medical tourism sectors, such as Cuba and Japan, indicating that China is still in the early stages of establishing a recognizable global brand in this field [18][25]. - The competition among Chinese cities to become the leading destination for medical tourism is intensifying, with initiatives and standards being developed to enhance service quality and attract more international patients [24][23].

Group 1 - The core point of the news is that Juzi Biotechnology has received approval from the National Medical Products Administration for its recombinant type I α1 collagen and sodium hyaluronate composite solution, marking a significant advancement in the high-end medical aesthetics regenerative materials sector [1][2] - The newly approved product is intended for injection into the dermis, primarily aimed at improving the smoothness of the cheeks, addressing a clear clinical need with limited supply in the market [1] - This product is the world's first implant that combines "recombinant collagen" and "sodium hyaluronate," potentially creating a new paradigm in facial rejuvenation treatments through a synergistic effect of "immediate filling + long-lasting regeneration" [1] Group 2 - Juzi Biotechnology holds two Class III medical device registration certificates in the medical aesthetics field, both of which have passed a stringent dual review process by the National Medical Products Administration, indicating superior safety, efficacy, and quality control [2] - The company leverages its synthetic biology technology platform to achieve breakthroughs in high-end regenerative materials, aligning with national strategic emerging industry directions [2] - There is an expectation for Juzi Biotechnology to accelerate the launch of more innovative products, contributing to the development of the biomanufacturing industry in China [2]

作为国内唯一同时持有合规"少女针"、"童颜针"两大再生填充产品，且同时还有肉毒毒素，水光针和黄 金微针等重磅叁类医疗器械医美品种的企业，四环医药童颜针凭藉左旋聚乳酸(PLLA)微球核心成分， 实现"即时填充+长效再生"的双重功效，其独特专利技术保障了微球形态规则、粒径均一，安全性与临 床疗效均表现优异，多数患者注射后1年仍能维持有效效果。此次规格拓展前，产品已获批45mg╱瓶、 75mg╱瓶、150mg╱瓶三类规格，分别适配预防型管理、联合治疗及综合年轻化等不同需求;新增获批 的60mg╱瓶、80mg╱瓶、100mg╱瓶、110mg╱瓶、120mg╱瓶、130mg╱瓶六类规格，将进一步丰富 产品选择谱系。 智通财经APP讯，四环医药(00460)发布公告，集团旗下渼颜空间生物科技(吉林)有限公司自主研发的聚 乳酸面部填充剂(市场简称"童颜针")6个新增规格正式获中国国家药品监督管理局批准，这是继该产品 首次获批后的又一重要进展，进一步完善了公司在再生医美产品领域的市场布局。 2.优化临床操作灵活性：依託产品1分钟快速复溶的特性，多规格选择让医生可根据注射部位、治疗层 次灵活调整稀释浓度与注射剂量，减少联合用药 ...

作为国内唯一同时持有合规「少女针」、「童颜针」两大再生填充产品，且同时还有肉毒毒素，水光针 和黄金微针等重磅三类医疗器械医美品种的企业，四环医药童颜针凭藉左旋聚乳酸(PLLA)微球核心成 分，实现「即时填充+长效再生」的双重功效，其独特专利技术保障了微球形态规则、粒径均一，安全 性与临床疗效均表现优异，多数患者注射後1年仍能维持有效效果。此次规格拓展前，产品已获批 45mg╱瓶、75mg╱瓶、150mg╱瓶三类规格，分别适配预防型管理、联合治疗及综合年轻化等不同需 求；新增获批的60mg╱瓶、80mg╱瓶、100mg╱瓶、110mg╱瓶、120mg╱瓶、130mg╱瓶六类规格， 将进一步丰富产品选择谱系。 格隆汇1月16日丨四环医药(00460.HK)宣布，集团旗下渼颜空间生物科技(吉林)有限公司("渼颜空间")自 主研发的聚乳酸面部填充剂(市场简称「童颜针」)6个新增规格正式获国家药监局批准，这是继该产品 首次获批后的又一重要进展，进一步完善了公司在再生医美产品领域的市场布局。 ...

Macro Economic Group - In December, M2 growth was 8.5%, exceeding Wind's expectation of 7.9% and up from 8.0% in November. M1 growth was 3.8%, matching expectations but down from 4.9% in November, indicating a slowdown in money velocity [4] - The total social financing (TSF) in December grew by 8.3%, slightly above the expected 8.2% but down from 8.5% in November. The TSF increment was 2.21 trillion yuan, surpassing the expected 1.82 trillion yuan but down from 2.49 trillion yuan year-on-year [4] - Bank credit in December increased by 910 billion yuan, exceeding the expected 679.4 billion yuan and up from 390 billion yuan in the previous month. However, it was down 800 billion yuan year-on-year [5] Industry Comprehensive Group - Siyi Electric (002028.SZ) reported a revenue of 21.2 billion yuan for 2025, a 37.2% year-on-year increase, with Q4 revenue reaching 7.38 billion yuan, up 46.1%. The net profit attributable to shareholders was 3.16 billion yuan, a 54.4% increase, exceeding market expectations [12] - Guanghe Technology (001389.SZ) forecasted a net profit of 980 million to 1.02 billion yuan for 2025, a growth of 45% to 50.8%. The Q4 net profit was estimated at 280 million yuan, a 50.4% increase, driven by strong demand for server PCB boards [13] Advanced Manufacturing Group - The UK AR7 offshore wind auction resulted in 8.4GW of capacity, exceeding expectations and marking a historical high. This sets the stage for significant supply chain orders in the coming years, with a peak delivery expected between 2028 and 2030 [15] - The State Grid has confirmed a total investment of 4 trillion yuan for the 14th Five-Year Plan, a 40% increase from the previous plan, focusing on accelerating ultra-high voltage construction and enhancing supply chain capabilities [16] Consumer Group - The Financial Regulatory Bureau emphasized the need for financial support to boost consumption and investment, particularly in sectors like real estate, healthcare, and small businesses. This is expected to benefit consumer sectors such as automobiles and home appliances [18] - Juzhi Bio's second collagen medical device has been approved, enhancing the focus on the collagen market, which is gaining traction in aesthetic and skin repair applications [19] - Liufeng Group reported a same-store sales growth of 15% for Q4 2025, driven by increased customer flow and product pricing strategies, indicating strong growth momentum [19]

四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 關於渼顏空間 渼 顏 空 間 是 四 環 醫 藥 精 心 孵 化「一 站 式」新 型 醫 美 平 台，通 過 全 球 化 佈 局、全 面 專 業 的 醫 美 產 品 矩 陣、產 品 研 發、註 冊、生 產 及 銷 售 一 體 化 架 構，致 力 於 以 製 藥 企 業 的 嚴 謹 創 新 打 造 匠 心 鑄 造 中 國 醫 美 全 產 品 矩 陣 龍 頭 企 業。渼 顏 空 間 持 續 的 完 整 產 品 矩 陣，管 線 內 共 包 含60餘 款 產 品，覆 蓋 了 包 括 填 充、塑 形、支 撐、 光 電 設 備 及 皮 膚 管 理 類 等 輕 醫 美 的 基 礎 類 別。同 時，渼 ...

Core Viewpoint - CICC maintains a "outperforming the industry" rating for Giant Bio (02367) with a target price of HKD 56, indicating a 55% upside potential based on 25/23x P/E for 2026-2027 [1] Recent Events - On January 15, Giant Bio announced the approval of its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness [2] - The approval of this product is expected to expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [2] Future Product Pipeline - The company has a rich pipeline for aesthetic medicine, with cross-linked neck wrinkle products receiving priority review status and cross-linked nasolabial fold products progressing smoothly [3] - The approval of the first two aesthetic products has confirmed the company's technological leadership and safety, with strong channel resources and operational experience expected to enhance future product launches [3] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for product and channel expansion, with a rich reserve of new products including the "Kemei" collagen repair series and plans for brand upgrades and new product launches in 2026 [4] - In terms of marketing, the company has strengthened its collaboration with key influencers, such as launching a New Year gift box with Li Jiaqi, and plans to enhance its online influencer matrix and self-operated team while expanding offline coverage [4]

Core Viewpoint - Company maintains a "outperforming the industry" rating for Giant Bio (02367) with a target price of HKD 56, indicating a potential upside of 55% based on 26-27 P/E ratios of 25x and 23x respectively, supported by strong R&D capabilities, brand recognition, and team cohesion [1] Recent Events - The company announced on January 15 that its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" has been approved as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness [2][3] - The approval is expected to expand the company's aesthetic product matrix and validate its leading technological R&D capabilities [2] Future Product Pipeline - The company has a rich pipeline of aesthetic products, including cross-linked neck wrinkle products that have received priority review status and cross-linked nasolabial fold products that are progressing smoothly [3] - The approval of the first two aesthetic products has confirmed the company's technological leadership and safety, with strong channel resources and operational experience that can be reused for future product launches [3] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for product and channel expansion, with a rich reserve of new products including the "Kefumei Collagen Repair," "Focus," and "Order" series set to launch [4] - The company plans to upgrade the "Keli Jin" brand and introduce new products by 2026, while also enhancing collaboration with key influencers like Li Jiaqi for promotional activities [4] - There is a focus on strengthening online influencer networks and self-operated teams, as well as expanding offline channels including cinema lines, OTC, and CS/KA channel coverage [4]

Core Viewpoint - The approval of the recombinant type I α1 collagen and sodium hyaluronate composite solution by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its position in the aesthetic medicine market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate for the composite solution, which is the first of its kind globally for improving cheek smoothness [1] - The product is primarily composed of recombinant collagen and sodium hyaluronate, intended for injection into the dermis [1] Group 2: Market Impact - The stock price of the company increased by 5.38%, reaching HKD 37.84, with a trading volume of HKD 16.51 million following the announcement [1] - CICC expressed optimism regarding the product's approval, which is expected to further expand the company's aesthetic product matrix and validate its leading technological research and development capabilities [1] Group 3: Future Strategy - The company plans to steadily advance the product's market launch and promotion through a diversified product portfolio, comprehensive channel network, and refined brand operations [1] - The aim is to provide differentiated solutions and continuously strengthen its leading market position in the health and beauty sector [1]

Core Insights - The 11th New Oxygen Asia-Pacific Aesthetic Medicine Industry Summit was held in Sanya, focusing on "value return" to reshape the technical value of doctors and promote high-quality industry development [1] - By 2025, the aesthetic medicine industry is expected to undergo structural changes, with an estimated 12,000 related enterprises being deregistered, a 50% increase compared to 2024, nearing historical peaks [1] - Consumers are increasingly rational, prioritizing qualifications, brand reputation, and professional expertise when choosing aesthetic institutions, with safety being the primary concern for treatment projects [1] Industry Trends - The aesthetic medicine market in China has reached a scale of hundreds of billions, expanding at a compound annual growth rate of 22.6%, making it one of the most promising core markets globally [2] - New Oxygen is leveraging its industrial platform and digital technology to implement "value return," enhancing service quality by curating high-quality merchants and streamlining SKUs to meet consumer demands for quality and diversity [2] - Despite the industry's transformation phase, there is a belief that the continuous release of aesthetic medicine demand will lead to new development opportunities, with a focus on maintaining medical value and team consensus during challenging external conditions [2] Event Highlights - The summit attracted nearly 400 industry representatives, including associations, brand institutions, and aesthetic doctors, and awarded over 260 prizes across 10 aesthetic medicine subfields [2]